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Abstract
Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are promising sources for the cell therapy of
muscle diseases and can serve as powerful experimental tools for skeletal muscle research, provided an effective method to
induce skeletal muscle cells is established. However, the current methods for myogenic differentiation from human ES cells
are still inefficient for clinical use, while myogenic differentiation from human iPS cells remains to be accomplished. Here, we
aimed to establish a practical differentiation method to induce skeletal myogenesis from both human ES and iPS cells. To
accomplish this goal, we developed a novel stepwise culture method for the selective expansion of mesenchymal cells from
cell aggregations called embryoid bodies. These mesenchymal cells, which were obtained by dissociation and re-cultivation
of embryoid bodies, uniformly expressed CD56 and the mesenchymal markers CD73, CD105, CD166, and CD29, and finally
differentiated into mature myotubes in vitro. Furthermore, these myogenic mesenchymal cells exhibited stable long-term
engraftment in injured muscles of immunodeficient mice in vivo and were reactivated upon subsequent muscle damage,
increasing in number to reconstruct damaged muscles. Our simple differentiation system facilitates further utilization of ES
and iPS cells in both developmental and pathological muscle research and in serving as a practical donor source for cell
therapy of muscle diseases.
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Introduction
Duchenne muscular dystrophy (DMD) is the most common and
well-investigated form of muscular dystrophy inherited in an X-
linked recessive manner. The molecular deficits underlying this
disorder are primarily involved in muscular structural integrity
and result in continuous damage to the muscles due to
contraction-induced mechanical stress. This damage leads to the
rapid wasting of skeletal muscles and to the early deaths of affected
patients [1]. Satellite cells, which are muscle-specific stem cells that
reside in the muscle [2], maintain the ability of skeletal muscles to
undergo self-repair and can be mobilized for reconstruction when
the muscles are damaged from exercise and daily activities [3–5].
Although muscular regeneration occurs at a higher frequency in
DMD patients than in non-affected individuals [6], it is insufficient
to maintain muscle function throughout life. If satellite cells were
able to restore damaged muscles more efficiently, the courses of
the diseases might be less severe, as observed in mdx mice, a DMD
model that is fertile and has a near-normal lifespan [1,7,8]. Despite
extensive efforts to develop pharmacological agents to halt the
clinical course of DMD, the disease still results in high mortality in
patients during late adolescence.
Cell replacement therapy using extrinsic myogenic cells is one of
the most promising treatment modalities for muscular dystrophies.
Somatic stem cells with skeletal myogenic potential, such as
myoblasts, mesenchymal stem cells, side population cells of
muscles and bone marrow, pericytes, and hemangioblasts, are
known to reside in various types of adult tissues. These cells
regenerate diseased muscles in mdx mice; however, clinical trials
involving allogeneic myoblast transplantation in DMD patients
have not obtained satisfactory results because of immune rejection,
rapid death, and the limited migration of transplanted myoblasts
[9–11].
Embryonic stem (ES) cells are totipotent stem cells derived from
blastocysts [12,13] and possess considerable advantages over
somatic stem cells. Because ES cells have theoretically unlimited
proliferative capacity, they could be a reliable cell source for
regeneration therapy, provided that an effective myogenic
differentiation protocol is established. Moreover, recently estab-
lished induced pluripotent stem (iPS) cells have also become an
attractive option for regeneration therapy because they possess
self-renewal and pluripotent properties equivalent to those of ES
cells [14–16]. Furthermore, the iPS cell technology enables the
generation of individualized stem cells and thereby contributes to
patient-oriented research, including developmental pathology,
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drug screening, and toxicity testing, which otherwise would be
impossible in humans [17–18].
Thus far, several groups have demonstrated myogenic differ-
entiation from human ES (hES) cells with different induction
strategies [10,19]. The first approach is to induce lineage-specific
differentiation by providing appropriate environmental factors,
such as culture media, substrates, or cytokines. A classical
approach is to induce myogenesis through the formation of
three-dimensional cell aggregates called embryoid bodies (EBs), in
which the differentiation processes of all 3 germ layers are
recapitulated. Although it is an effective myogenic strategy
employed for murine ES research [20,21], this method had not
been successfully executed in human ES cells because of various
difficulties [22], until recently [23,24]. However, the differentia-
tion efficacy of these EB methods remains low and heterogeneous,
and the potential of EB methods as a donor source for cell
replacement therapy has not been investigated. Barberi et al.
reported another two-dimensional culture protocol in which hES
cells give rise to myogenic mesenchymal precursors. These
precursor cells show efficient in vitro differentiation into skeletal
myotubes and stable engraftment capacity in vivo [25,26].
However, from a practical perspective, this approach is difficult
to use because it requires repetitive cell sorting to obtain a
population of homogenous myogenic mesenchymal progenitors.
Another approach to achieve myogenic differentiation is the use of
genetic modification to directly activate myogenic signaling
pathways. Forced expression of MyoD is known to transform
fibroblasts to skeletal muscle cells [27], and is also applicable to
murine ES cells [28]. Darabi et al. demonstrated that the forced
expression of PAX3 successfully induced paraxial mesodermal and
subsequent myogenic differentiation in murine ES cells [29], and
the induction of PAX7 efficiently induced myogenesis both in
human ES and iPS cells [30]. These methods are indeed effective
myogenic strategies. However, genetic modification is accompa-
nied by various concerns, such as potent tumorigenesis.
We previously reported on an EB-based culture method that
induces efficient myogenesis from both murine ES and iPS cells, and
described the purification of satellite-like cells and their persistent
engraftment capacity in vivo [31,32]. The aims of this study were to 1)
establish a novel in vitro culture system to induce efficient myogenesis
from both human ES and iPS cells by modifying our EB-based
method, without introducing any additional genes; and 2) investigate
the capacity of the differentiated cells to engraft and repair damaged
muscles in vivo to clarify whether they are an appropriate donor source
in muscle regenerative medicine. Here, we describe a novel culture
method for efficient myogenesis by using selective expansion of
myogenic mesenchymal cells in vitro and demonstrate their capacity to
engraft in vivo.
Materials and Methods
Maintenance of human ES and iPS cells
The hES cell line KhES1 was a kind gift from Dr. Norio Nakatsuji
(Kyoto University, Kyoto, Japan) [33]. The hiPS cell lines 201B6,
201B7, 253G1, and 253G4 were established from human dermal
fibroblasts by retrovirus-mediated transfection of 4 (201B6 and 201B7)
or 3 (253G1 and 253G4) transcription factors (Oct3/4, Sox2, andKlf4,
with or without c-Myc) [15,16]. The human ES and iPS cell lines were
maintained on mitomycin-C (Kyowa Hakko Kirin, Tokyo, Japan)-
treated SNL feeder cells in human ES cell maintenance medium
[hESM: DMEM/F12 (Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 20% KnockoutH Serum Replacement (Invitrogen,
Carlsbad, CA, USA), 1%nonessential amino acid solution (Invitrogen),
5 mM sodium hydroxide solution, 100 mM 2-mercaptethanol, 2 mM
L-glutamine] with 5 ng/ml basic fibroblast growth factor (R&D
Systems, Minneapolis, MN, USA). The culture medium was changed
daily. Colonies were passaged every 4 or 5 days.
The human ES and iPS cell lines were used in conformity with
The Guidelines for Derivation and Utilization of Human
Embryonic Stem Cells of the Ministry of Education, Culture,
Sports, Science and Technology, Japan.
Skeletal muscle differentiation
EB culture (Figure 1, Left): Undifferentiated human ES and iPS
cells were trypsinized and floated in hESM as clusters for 7 days to
form EBs. These EBs were then transferred to 0.1% gelatin-coated
tissue culture plates and cultured in ITS medium [DMEM
supplemented with ITS-X (Invitrogen), nonessential amino acids
(Invitrogen), GlutamaxH supplement (Invitrogen), and 100 mM 2-
mercaptoethanol (Wako, Osaka, Japan)] for 14 days. Afterwards,
the medium was changed to skeletal muscle induction medium
[SkIM: high-glucose DMEM supplemented with 10% fetal calf
serum (FCS; Invitrogen), 5% horse serum (HS; Sigma), nonessen-
tial amino acids (Invitrogen), and 100 mM 2-mercaptoethanol
(Wako)]. The cells were analyzed on days 7, 21, 35, 49, 63, 84, and
112. The medium was changed every 3 to 4 days.
Figure 1. Schematic presentation of the differentiation protocol. Two different differentiation protocols were compared (Left: embryoid
body (EB) culture, Right: Dissociation culture) and were exactly the same until the first 21 (7+14) days of culture. On the left side, EBs continued to be
incubated in serum-containing medium without specific manipulation until the end of culture. On the right side, EBs and their outgrowth cells were
dissociated and seeded onto collagen type I-coated tissue culture plates in serum-containing medium. The medium was changed to serum-free ITS
medium on day 49 (7+14+28). In some experiments, the cells were harvested and used as donor cells for the transplantation assay at this time point.
doi:10.1371/journal.pone.0051638.g001
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Dissociation culture (Figure 1, Right): In some experiments, EBs and
their outgrowth cells were treated with 0.25% trypsin/EDTA on day
21 and seeded onto collagen type I-coated tissue culture plates (BD
Bioscience, Bedford, MA, USA) at a density of 3000 cells/cm2 in
SkIM. On day 49, the medium was changed to ITS medium. For
obtaining mature myofibers, cells were cultivated for up to 70 days.
The differentiated cells were analyzed on days 7, 21, 49, 56, 63, and 70.
Complementary DNA (cDNA) synthesis and reverse
transcription-polymerase chain reaction (RT-PCR)
Cells were trypsinized on the indicated days of differentiation.
Total RNA samples were extracted using silica gel membrane-
based spin columns (RNeasy Mini-KitH, Qiagen, Valencia, CA,
USA). cDNA samples were synthesized using the Ominscript-RT
KitH (Qiagen) and used for subsequent PCR. All procedures were
performed according to the manufacturer’s instructions. The
cDNA templates were initially denatured at 94uC for 5 min,
followed by 35 amplification reactions consisting of 94uC for 30
seconds (denaturing), 55–60uC for 30 seconds (annealing), and
72uC for 60 seconds (extension), with a final extension at 72uC for
7 min. Oligonucleotide primers were designed for Oct3/4, Nanog,
Pax3, Pax7, Myf5, MyoD, Myogenin, Desmin, TUBB3, TNNI3,
and GAPDH. The primer sequences and temperature settings are
described in supplemental materials (Table S1).
Flow cytometric (FCM) analysis
Staining procedures, FCM analysis, and cell sorting were
performed as described previously [31,32]. Cells trypsinized on the
Figure 2. Skeletal muscle development from human embryonic stem (hES) and human induced pluripotent stem (hiPS) cells by the
EB culture method. (A) PAX3- and PAX7-positive nuclei emerged in the proximal area of the embryoid body (EB)-outgrowth cells derived from hES
KhES1 cells. (B) Simultaneous derivation of neural and cardiac cells in the EB-outgrowth cells derived from hES KhES1 cells. Upper: TUJ1-positive
neural cells observed on day 7+28. Lower: Neural cells (outlined arrowheads) and colonies of beating cardiomyocytes (white arrowhead) appeared on
day 7+28. (C) Skeletal myosin-positive myofibers in the EB-outgrowth cells derived from human embryonic stem (hES) KhES1 cells detected on day
7+42. (D) Sequential analysis of undifferentiated and skeletal myogenesis-related gene expression by semi-quantitative RT-PCR. (E) Skeletal myosin-
positive fibers from human induced pluripotent stem (hiPS) cells. Four hiPS cell-lines were used. hiPS 201B6 on day 7+105, hiPS 201B7 on day 7+105,
hiPS 253G1 on day 7+77, and hiPS 253G4 on day 7+56. (F) Sequential analysis of undifferentiated and skeletal myogenesis-related gene expression by
semi-quantitative RT-PCR. In (A-C) and (E), antibodies were visualized using Cy3 (red). Nuclei were counterstained with DAPI (blue). Scale bars = 100
mm.
doi:10.1371/journal.pone.0051638.g002
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indicated days of differentiation were stained with phycoerythrin-
or allophycocyanin-conjugated primary antibodies (Abs). Abs used
for FCM analysis included mouse anti-CD73, anti-CD105, anti-
CD166, anti-CD34, anti-CD56, anti-CD106 (BD Bioscience), and
anti-CD29 (Beckman Coulter, Brea, CA, USA). Dead cells were
excluded by propidium iodide (Sigma). Samples were analyzed
using FACSCalibur (BD Bioscience) and Cell Quest software (BD
Bioscience).
Immunostaining assays
Immunofluorescence analyses were performed as previously
described [31,32]. Briefly, samples were fixed for 5 min in 4%
paraformaldehyde (PFA) and then permeabilized with 0.1%
Triton X-100 in phosphate-buffered saline (PBS) for 10 min.
After incubation in 2% skim milk for 1 h at room temperature to
block nonspecific antibody binding, cells were incubated with
primary antibodies for 1 h at room temperature. The primary
antibodies used in this study were as follows: mouse anti-Pax3
(R&D Systems, Minneapolis, MN, USA), mouse anti-Pax7 (R&D
Systems), rabbit anti-Myf5 (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), mouse anti-MyoD1, mouse anti-myogenin
(Dako, Carpinteria, CA, USA), mouse anti-fast twitch myosin
heavy chain (MYH2) (MY32; Zymed Laboratories, San Francisco,
CA, USA), rabbit anti-skeletal myosin (Sigma), mouse anti-
dystrophin (MANDRA1; Sigma), rabbit anti-laminin (Dako),
mouse anti-human merosin (Laminin alpha 2), mouse anti-human
lamin A/C (Novocastra Laboratories, Newcastle-upon-Tyne,
UK), mouse anti-beta-tubulin III (TUJ1) (Sigma), and rabbit
anti-glial fibrillary acidic protein antibody (GFAP) (Sigma). After
washing twice with PBS, samples were incubated with secondary
antibodies for 1 h at room temperature. The secondary antibodies
used in this study were Cy3-conjugated anti-mouse IgG (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA, USA) and
fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG
(Jackson ImmunoResearch). DAPI was used for nuclear staining.
These samples were then examined using fluorescent microscopes
(FluoView System; Olympus, Tokyo, Japan). Photographs were
acquired with an Axio-Cam (Carl Zeiss Vision, Hallbergmoos,
Figure 3. Characterization and differentiation of the derived myogenic mesenchymal cells. (A) Morphology of the derived myogenic
mesenchymal progenitors 2 days (day 7+14+2) and 4 weeks (day 7+14+28) after replating. Homogeneous spindle-shaped fibroblastic cells were
observed. (B) Surface marker analysis of myogenic mesenchymal progenitors. Representative data from KhES1 differentiation are shown. Note that
CD56 in addition to mesenchymal markers CD73, CD105, CD166, and CD29 was exclusively expressed. (C) Changes in the expression of myogenic
markers were analyzed by immunofluorescence. The number of Cy3-positive nuclei was divided by the total number of nuclei stained by DAPI. The
expression of myogenic progenitor markers decreased after exposure to serum-free medium, whereas the number of MYOG-positive cells
substantially increased after serum deprivation. (D) Changes in the number of MYOG-positive nuclei were observed up to 3 weeks after serum
deprivation. hES/iPS-derived myofibers tended to detach from tissue culture plates during long-term culture in serum-free medium. (E) Serum
deprivation increased the number of skeletal myosin-positive fibers and MYOG-positive nuclei for more than 2 weeks. KhES1 was used in this figure.
(F) Multinucleated myofibers denoted by MYOG myogenin-positive nuclei aligned in skeletal myosin-positive fibers. (G) Morphology of mature
myofibers, which were stained with skeletal myosin, MYOG, and dystrophin, from both KhES1 and 253G4 cells. Skeletal myosin was visualized with
fluorescein isothiocyanate (FITC) (Green), myogenin was visualized with Cy3 (red), and nuclei were counterstained with DAPI (blue). Scale bars = (C,
E) 100 mm, (D) 50 mm.
doi:10.1371/journal.pone.0051638.g003
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Germany). To quantify myogenic transcription factor-positive
cells, we counted the number of Cy3-positive nuclei and divided
this value by the total number of nuclei stained by DAPI.
For triple staining, we modified the protocol described by
Darabi and his colleagues [30]. Briefly, samples were fixed for 20
min in 4% PFA, followed by permeabilization using 0.3% Triton
X-100 in PBS. After incubation in blocking solution consisting of a
mixture (1:1) of 3% bovine serum albumin (Invitrogen) and MOM
blocking agent (Vector Laboratories Inc., Burlingame, CA, USA)
for 1 h at room temperature, the slides were incubated with mouse
anti-Pax7 (R&D Systems). After washing twice with PBS, samples
were incubated with alexa-fluor 555 conjugated anti-mouse IgG
(Invitrogen) for 30 min. After washing twice, the slides were
blocked using the same solution for 1 h at room temperature.
Subsequently, the slides were incubated with mouse anti-human
Lamin A/C (Novocastra) and rabbit anti-laminin (DAKO) for 1 h
at room temperature, followed by incubation with alexa fluor 488-
conjugated anti-mouse IgG and alexa fluor 647-conjugated anti-
rabbit IgG (Jackson Immunoresearch). The nuclei were counter-
stained using DAPI and analyzed by AS-MDW system (Leica
Microsystems GmbH, Wetzlar, Germany).
Transplantation
Eight-week-old male immunodeficient NOD/Shi-scid/IL-
2Rcnull (NOG) mice (Central Laboratories for Experimental
Animals, Kanagawa, Japan) [34] were used as host mice to avoid
immunological rejection. Host tibialis anterior (TA) muscles were
bilaterally injected with 50 mL of 10 mM cardiotoxin (CTX;
Latoxan, Valence, France) to induce muscle degeneration 24 h
before transplantation. These mice were systemically irradiated to
block endogenous muscle regeneration. Irradiation was delivered
in 2 fractions of 1.2 Gy, a sub-lethal dose for NOG mice. The cells
(1.06105 or 5.06105) were suspended in 20 mL of medium and
directly injected into the pre-damaged left TA muscles. The same
amount of medium was injected into the right TA muscles, which
served as the control. Mice were sacrificed at 4, 12, and 24 weeks
Figure 4. Engraftment of myogenic progenitors in damaged muscles of immunodeficient mice. (A) Human nuclei labeled with human-
specific lamin A/C localized mainly inside muscle fibers surrounded by laminin. (B) Muscle reconstruction by transplanted human cells was
demonstrated by the detection of human-specific laminin-alpha 2. (C) The proportion of myofibers containing human nuclei at 4, 12, and 24 weeks
after transplantation. (D) The proportion of myofibers containing human nuclei in reinjured (3+1 weeks) and in non-reinjured mice (4 weeks) at 4
weeks after transplantation. In C and D, data are presented as the mean 6 standard deviation. (E) Distribution of the transplanted cells at 24 weeks
after transplantation. Typical central nuclei of human origin were observed (outlined arrowheads). Some human cells located within the lamina rara
beneath the basal lamina, indicating engraftment of the transplanted cells into a satellite cell compartment (white arrowhead). (F) Triple-staining for
human Lamin A/C, PAX7, and pan-Laminin clearly demonstrated the existence of PAX7-positive human nuclei indicating the transplanted cells
engrafted as satellite cells (white arrowhead). Human lamin A/C-negative host satellite cells were also detected (outlined arrowhead). Laminin was
stained by a polyclonal antibody that recognizes both human and murine laminin, and was subsequently visualized with fluorescein isothiocyanate
(FITC) (Green); human lamin A/C and human-specific laminin, with Cy3 (red). Nuclei were counterstained with DAPI (blue). Scale bars = (A) 100 mm,
(B) and (E) 50 mm.
doi:10.1371/journal.pone.0051638.g004
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after transplantation and subjected to immunohistological analy-
ses. In some experiments, the transplanted mice were re-injured by
CTX injection at 3 weeks after transplantation and analyzed 1
week later to determine the regenerative capacity of the engrafted
cells. For the immunohistological assay, the isolated muscles were
frozen in isopentane cooled in liquid nitrogen. The frozen
specimens were sectioned with a cryostat (CM1850; Leica
Microsystems, Wetzlar, Germany) and analyzed as described
above. All animal handling procedures were followed according to
the Guide for the Care and Use of Laboratory Animals published
by the U.S. National Institutes of Health (NIH Publication No.
85–23, revised 1996) and the Guidelines of the Animal Research
Committee of the Graduate School of Medicine, Kyoto Univer-
sity. This work was approved by the Animal Research Committee
of the Graduate School of Medicine, Kyoto University. Mice were
sacrificed by cervical dislocation. All painful procedures including
cervical dislocation were performed under anesthesia. In immu-
nofluorescence analyses, the percentage of human nuclei in total
nuclei was counted.
Statistics
Statistical analyses were performed using the unpaired Student’s
t test, and a value of P,0.05 was considered to be statistically
significant.
Results
Myogenic induction by human ES and iPS cells in EB
outgrowth culture
To develop an efficient differentiation protocol for inducing
skeletal myogenesis from human ES and iPS cells, we adapted our
previously established EB-based method that induces myogenic
differentiation from murine ES and iPS cells [31,32]. EBs were
formed by suspension in hESM for 7 days and then plated onto
0.1% gelatin-coated tissue culture plates. Attached EBs were
cultured in serum-free medium for an additional 14 days and then
in differentiation medium containing 10% FCS and 5% HS until
day 112 (7+14+91) of differentiation. When EBs attached to the
plates, the cells migrating out from the EBs formed a single layer,
which we termed an EB-outgrowth (EB-OG). Immunostaining for
PAX3 and PAX7, which mark early myogenic progenitors,
showed that clusters of PAX3- and PAX7-positive cells were
randomly distributed at day 21 (Figure 2A). Skeletal myosin
(MYH)-positive multinucleated myofibers had appeared within
most of the attached EBs at day 63 (Figure 2C) and were randomly
distributed in the crowded EB-OG. Some attached EBs simulta-
neously contained TUJ1-positive neural cells (Figure 2B) and
colonies of beating cardiomyocytes (Figure 2B), as previously
observed in studies on murine EB differentiation [20,21].
We then analyzed the expression of genes associated with
skeletal myogenesis, including PAX3, PAX7, desmin (DES), and the
Table 1. Transplantation efficacy demonstrated by the percentage of human nuclei in the transplanted muscles.
KhES1 Average SD 253G4 Average SD
* 4 weeks #1–1 15.1% 17.3%
* 4 weeks #1–2 13.0% 18.6%
* 4 weeks #2–1 8.1% 7.4%
* 4 weeks #2–2 16.1% 6.1%
** 4 weeks #3–1 12.6% 7.2%
** 4 weeks #3–2 15.8% 13.5% 2.7% 10.3% 11.1% 5.0%
* 12 weeks #1–1 26.5% 11.7%
* 12 weeks #1–2 29.3% 10.3%
* 12 weeks #2–1 13.5% {
* 12 weeks #2–2 16.5% 9.5%
** 12 weeks #3–1 17.6% 11.7%
** 12 weeks #3–2 ND 20.7% 6.1% 11.5% 10.9% 0.9%
* 24 weeks #1–1 16.2% 12.2%
* 24 weeks #1–2 13.9% 9.3%
* 24 weeks #2–1 16.3% 9.6%
* 24 weeks #2–2 20.9% 8.1%
** 24 weeks #3–1 16.3% 11.4%
** 24 weeks #3–2 19.6% 17.2% 2.3% 11.1% 10.3% 1.4%
** 4 weeks #4–1 12.3% 6.9%
** 4 weeks #4–2 14.6% 11.9%
** 4 weeks #4–3 10.4% 12.5% 1.7% 15.7% 11.5% 3.6%
** 3+1 weeks #4–1 30.4% ND
** 3+1 weeks #4–2 25.8% 13.0%
** 3+1 weeks #4–3 40.7% 32.3% 6.3% P,0.05 24.7% 18.9% 5.8% NS
The number of cells of human origin was divided by the number of total nuclei stained by DAPI. The result also appears in Figures 4C and 4D. SD: standard deviation.
ND: not detected. *, ** indicate the cell numbers transplanted at the site: * 5.06105 cells/site, ** 1.06105 cells/site. {: One mouse transplanted with 253G4-derived cells
died accidentally before analysis. NS: statistically not significant.
doi:10.1371/journal.pone.0051638.t001
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muscle regulatory factors MYF5, MYOD, and MYOG (Figure 2D).
The expression of PAX3 was first detected on day 7, increased at
day 21 (7+14), and decreased thereafter. PAX7, which is essential
for the specification of muscle progenitors [3-5,35,36], was
detected at day 21 (7+14), but its expression was highly variable.
MYOD and DES were first detected at day 21 (7+14), and their
expression increased thereafter. MYF5 was detected at day 7, and
its expression was sustained throughout differentiation. The
expression of MYOG was not detected until day 49 (7+42) but
increased thereafter. In contrast, the pluripotent stem marker
genes OCT3/4, NANOG, and REX1 were down regulated during
differentiation. Thus, the hierarchical expression of myogenic
genes in this system was similar to the patterns observed during
murine embryogenesis [37] and to those of the EB differentiation
of murine ES and iPS cells [20,31,32].
To verify whether this protocol was applicable to hiPS cells, we
used 4 iPS cell lines expressing either 4 (OCT3/4, SOX2, NANOG,
and MYC) [15] or 3 (lacking MYC) retrovirally introduced
transcription factors [16]. The EBs from all examined hiPS cell
lines contained MYH-positive myofibers, confirming the myogenic
potential of hiPS cells (Figure 2E). The expression pattern of
myogenic markers was quite similar to that of ES cells (Figure 2F),
although the differentiation efficacy was different among the cell
lines.
Thus, EB-OG successfully induced myogenesis from both
human ES and iPS cells, thereby simulating the temporal
patterning of embryogenesis. However, the EB-OGs were so
heterogeneous that we could not distinguish the differentiated
muscle lineage cells from other lineage cells. Most of the skeletal
muscle lineage cells appeared as clusters in crowded EB-OGs and
never appeared as a homogeneous population.
Selective expansion of myogenic mesenchymal cells
from dissociated EB outgrowth culture
Because mature myofibers could not clearly be distinguished in
the overcrowded EB-OG cells, we decided to purify the myogenic
cells from the other EB-OG cells. We hypothesized that the
separation of the myogenic cells might allow efficient myogenesis if
these other lineage cells were disturbing skeletal myogenesis in the
EBs. Hence, the differentiated EB-OG cells were dissociated into
single cells and re-cultured on collagen type I-coated plates on day
21 (7+14) when the clusters of PAX3- and PAX7-positive
myogenic progenitors were detected. When the dissociated cells
were replaced onto collagen type I-coated plates, cells with a
uniform spindle, fibroblastic morphology developed selectively
during the next 4 weeks (Figure 3A). FCM analysis showed that
the generated cells exclusively expressed the mesenchymal markers
CD73, CD105, CD166, and CD29, whereas CD34 and CD106
were hardly detected. CD56 (NCAM; neural cell adhesion
molecule) was also highly expressed (Figure 3B, Figure S1). A
low-density culture of dissociated cells on collagen type I was
crucial for selective development of myogenic cells; neural and
cardiac cells were not detected in this dissociation protocol
(Figure S2).
Quantification of the expression of the myogenic progenitor
markers MYOD, MYF5, and PAX7 increased during cell
proliferation and peaked around day 49 (7+14+28) in this
dissociation protocol. Since serum deprivation is known to
enhance further maturation of myogenic cells, we switched from
serum-containing SkIM to serum-free ITS medium to induce
terminal muscular differentiation. Following serum deprivation,
the proportion of myogenic progenitor marker-positive nuclei
decreased immediately, whereas that of MYOG-positive nuclei
dramatically increased (Figure 3C–3E). The increased expression
of skeletal myosin-positive fibers and the increased prevalence of
MYOG-positive nuclei were maintained up to 3 weeks (Figure 3C,
3D).
Both hES (KhES1) and hiPS (253G4) cell-derived cells fused
together and produced multinucleated myofibers that were
positive for skeletal myosin and dystrophin (Figure 3F, 3G). These
myofibers occasionally showed spontaneous contraction, indicat-
ing the maturation of skeletal muscle cells. Hence, the results
showed that this multi-step culture method selectively isolated
myogenic mesenchymal population from dissociated EB culture,
and that these myogenic mesenchymal cell populations could
terminally differentiate into functionally mature myofibers in vitro.
Transplantation in immunodeficient NOG mice
Next, we examined the in vivo myogenic potential of human ES
and iPS cell-derived myogenic mesenchymal cells by transplanting
them into the injured muscles of NOG mice. As myogenic
progenitor markers were strongly expressed at day 49 (7+14+28),
the cells were trypsinized again and used as donor cells. To avoid
immunological rejection, we used immunodeficient NOG mice as
the hosts.
Four weeks after transplant, human-specific lamin A/C-positive
nuclei were detected in TA muscles (Figure 4A). Human lamin A/
C-positive and lamin A/C-negative nuclei were co-localized in the
same muscle fascicle and had formed hybrid myotubes (Table 1,
Figure 4A). Furthermore, the detection of human-specific merosin
(laminin alpha 2) proved that the transplanted cells had not only
survived within muscle fibers but had also produced human
protein around the muscle fibers into which they had integrated
(Figure 4B). Thus, the myogenic mesenchymal cells derived here
engrafted and functioned to repair damaged muscles.
We also investigated the log-term outcome of the myogenic
mesenchymal cell transplant. Human lamin A/C-positive nuclei
were continuously observed in the damaged muscles until 24
weeks after transplantation (Table 1, Figure 4C). Moreover, the
presence of typical central nuclei of human origin strongly
suggested that transplanted cell-related muscular regeneration
occurred even at 24 weeks after transplantation (Figure 4E).
Although most human cells were detected within muscle fascicles,
some of them resided within the lamina rara, which is consistent
with the location of satellite cells (Figure 4E). These human nuclei
were also positive for PAX7, confirming the contribution of the
transplanted cells to the satellite cell fraction (Figure 4F). Under
macroscopic and histological examination, teratoma formation
was not observed up to 24 weeks.
Finally, to assess whether the engrafted myogenic mesenchymal
cells could proliferate in response to subsequent damage, we
employed a second injury model, as previously reported [31,32].
Three weeks after transplantation, CTX was directly injected into
the transplanted muscles. The proportion of human nuclei was
higher in re-injured mice than that in non-re-injured mice at 4
weeks after transplantation in the experiment using hES cells,
whereas no statistical significance was observed in the hiPS cells.
(Table 1, Figure 4D).
Collectively, our results indicated that human ES and iPS cell-
derived myogenic mesenchymal cells engrafted effectively, inte-
grated into the satellite cell fraction, and contributed to the long-
term reconstruction of the damaged muscle tissue without
exhaustion.
Discussion
Recent remarkable advances in human ES and iPS cell
technology have increased the demand for the clinical application
Myogenic Mesenchymal Cells from Human ES/iPS Cells
PLOS ONE | www.plosone.org 7 December 2012 | Volume 7 | Issue 12 | e51638
of these cells and their use in basic research. The excellent work by
Barberi et al. clearly demonstrated the myogenic capacity of hES
cells both in vitro and in vivo [26]; however, their strategy to obtain
myogenic populations included repetitive cell sorting procedures,
which would hamper practical use. The other approach to induce
myogenesis from hES cells is to form EBs; however, the EB-based
methods inevitably contain cells from other lineages. Ideally,
homogeneous populations of the desired cell types should be
generated using a simple method that does not involve compli-
cated procedures.
In this report, we modified our murine ES and iPS cell culture
system to develop a new EB-based culture method that can
successfully induce mature skeletal muscle cells from hES cells. An
advantage of this system is that selective expansion of myogenic
mesenchymal cells can be accomplished by simple manipulation.
Moreover, this culture system is applicable to hiPS cells. Darabi
and his colleagues recently reported successful skeletal muscle
induction from hiPS cells by PAX7 overexpression [30]. However,
skeletal myogenesis from hiPS cells without genetic manipulation
has not been previously reported. Our results facilitate the further
use of hiPS cells in muscle regenerative medicine, which extends
the possibilities of hES technology to clinical applications, such as
patient-oriented research and autologous transplantation [10,17–
19].
We did not employ cell sorting in this method. Several reports
have demonstrated that multipotent mesenchymal cells can be
generated by long termEB culturing or repetitive passaging [38,39].
Meanwhile, some subpopulations of mesenchymal stem cells
(MSCs) are considered to possess myogenic potential. We re-plated
dissociated EBs on several coating materials (Figure S2), and
derived the immunophenotypically homogeneous mesenchymal
cell population. Surface marker analyses demonstrated that the
generated cells were uniformly positive for mesenchymal stem cell
(MSC)-related surface antigens, including CD73, CD105, CD166,
and CD29. However, the generated cells were different fromMSCs
because of the high expression of CD56. CD56 is known to be
expressed in embryonic skeletal muscles and satellite cells [9,11],
and was used for the prospective isolation of myogenic progenitors
fromhES cell-derivedMSCs in a previous report [26]. These reports
also supported the existence of the myogenic mesenchymal cells
generated here. Further study will be necessary to characterize the
derived cells in terms of their multipotency, including their
osteogenic, chondrogenic, and adipogenic activities.
The homogenous mesenchymal population with myogenic
potential developed in our culture system; these can be used for
both in vitro and in vivo studies. By depleting serum, the transition
from myogenic progenitors to mature myotubes can easily be
observed during culture. In combination with the recent
advancements in creating disease-specific hiPS cell lines, this
culture system will be a powerful experimental tool for disease
studies and the screening of drugs for various types of muscle
diseases, both of which have been difficult to conduct because of
the significant challenge in obtaining sufficient materials.
Furthermore, we demonstrated the in vivo myogenic capacity of
derived cells. When transplanted in NOG mice, the engrafted cells
contributed to satellite cell fraction and reconstructed the injured
muscles up to at least 6 months without rejection. Moreover, the
integrated cells showed a more robust proliferation in response to
subsequent injury. Myogenic progenitors with such re-prolifera-
tion capacity in vivo have not been reported in previous studies
[22–26,29,30], and can be a feasible cell source for muscle
regenerative medicine, since long-lasting muscle repair will be
required for patients with genetic muscle diseases. The risk of
teratoma formation was eliminated by selective culture conditions,
which is also suitable for clinical settings.
The underlying mechanisms of the selective proliferation of
myogenic cells in our culture system remain unresolved. The
initial EB-OG culture simultaneously contained neuronal and
cardiac cells in addition to muscle lineage cells. Given that re-
plating the dissociated cells at low cell density was a crucial step for
effective myogenic differentiation, direct cell-to-cell contact or
soluble factors from other cells or cell lineages might have
negatively affected the selective development of muscle lineage
cells. Otherwise, simple cell selection through the capacity to
adhere to collagen type I-coated plates or differences in
proliferation potential enriched the myogenic mesenchymal
population in the residual cells (Figure S2).
In conclusion, we have reported a novel culture system that
induces homogenous myogenic mesenchymal cells from both
human ES and iPS cells. This method is a modification of the
widely used EB method and is accomplished using a simple
procedure. To date, there still are few reports describing human
ES and iPS cell myogenic differentiation. This system encourages
further utilization of human ES and iPS cells in skeletal muscle
research, which could not otherwise be conducted in humans, and
will provide a promising therapeutic approach for various muscle
diseases.
Supporting Information
Figure S1 Surface marker changes with or without EB
dissociation. Surface marker of the differentiating EBs without
dissociation (left) and the cells after EB dissociation and re-plating
(right). The mesenchymal stem cell marker, CD73, increased
during continuous EB culture, but much homogeneous population
was obtained at days 7+14+28 by EB dissociation. Representative
histograms are shown. The experiments were conducted 3 times,
and mean scores and standard deviations were calculated. SD:
standard deviation.
(TIF)
Figure S2 Elimination of other lineage cells by low-cell-
density culture on collagen type I. The results demonstrated
that low-density culture on collagen type I eliminated neural and
cardiac cells. (A) RT-PCR for TUBB3, TNNI3, and Desmin
expression at different cell densities. RT-PCR result indicated
contamination of neural and cardiac cells at high-density culture at
variable levels. Laminin and poly-D-lysin preferentially captured
many more neurogenic cells, whereas others did not. At low-
density culture, 0.1% gelatin, laminin, and poly-D-lysin could not
support cell proliferation. A heterogeneous non-mesenchymal
population was obtained on collagen type IV. When cultured on
MatrigelH, the results obtained were similar to that obtained using
collagen type I. (B) TUJ1- or GFAP-positive cells observed at high-
cell-density culture on collagen type I. At high cell density, the cells
reached confluence at several days after re-plating. Upper: 7 days
after re-plating. Lower: 28 days after re-plating. No neural cells
were detected if cultured at a low-density.
(TIF)
Method S1 Selection of myogenic cells by low-cell-
density culture on collagen type I EBs were dissociated
at day 21 (7+14) of differentiation and re-plated onto
different coating materials. We used 0.1% gelatin, laminin,
poly-D-lysin, collagen type I, collagen type IV, and MatrigelH (All
from BD Bioscience) for the experiments. The cells from
dissociated EBs were seeded at low- or high-cell-density (3,000
and 30,000 cells/cm2, respectively) and cultured for up to 28 days.
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Cells were analyzed at day 7 and 28 after re-plating by RT-PCR
or immunostaining.
(DOCX)
Table S1 The primer settings used for RT-PCR.
(TIF)
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